Grifols (NASDAQ:GRFS) Releases Quarterly Earnings Results, Beats Expectations By $0.14 EPS

Grifols (NASDAQ:GRFS) released its earnings results on Monday. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.32 by $0.14, FiscalAI reports. Grifols had a net margin of 5.54% and a return on equity of 6.21%.

Grifols Stock Up 4.4%

GRFS stock traded up $0.35 during mid-day trading on Monday, reaching $8.46. 867,765 shares of the company traded hands, compared to its average volume of 642,344. The company has a quick ratio of 0.81, a current ratio of 2.37 and a debt-to-equity ratio of 1.10. The firm’s 50 day moving average price is $7.59 and its 200 day moving average price is $8.01. The stock has a market cap of $5.75 billion, a price-to-earnings ratio of 44.50, a P/E/G ratio of 0.29 and a beta of 0.75. Grifols has a fifty-two week low of $6.96 and a fifty-two week high of $9.90.

Analyst Upgrades and Downgrades

GRFS has been the topic of a number of research analyst reports. Wall Street Zen cut shares of Grifols from a “buy” rating to a “hold” rating in a research report on Saturday, October 10th. Weiss Ratings raised Grifols from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, August 17th. Zacks Research raised Grifols from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 7th. Finally, JPMorgan Chase & Co. dropped their price target on Grifols from $10.00 to $9.00 and set a “neutral” rating on the stock in a research note on Monday, October 26th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average price target of $9.00.

About Grifols

Grifols SA is a global healthcare company headquartered in Barcelona, Spain, specializing in plasma-derived medicines and diagnostic technologies. The company develops, manufactures and markets therapies made from human plasma, including immunoglobulins, albumin and coagulation factors used to treat immune deficiencies, bleeding disorders and other chronic conditions.

Grifols operates a vertically integrated plasma business that includes plasma donation centers, collection and fractionation facilities, research and development, manufacturing and distribution.